CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y **ao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
T Yan, L Zhu, J Chen - Experimental Hematology & Oncology, 2023 - Springer
The past decade has witnessed ongoing progress in immune therapy to ameliorate human
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
Advances in universal CAR-T cell therapy
H Lin, J Cheng, W Mu, J Zhou, L Zhu - Frontiers in immunology, 2021 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements
results in antitumor treatments, especially against hematological malignancies, where it …
results in antitumor treatments, especially against hematological malignancies, where it …
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
M Wermke, S Kraus, A Ehninger… - Blood, The Journal …, 2021 - ashpublications.org
COI notes: AE, JK, MP, GE, and MC are employed by and/or hold shares of GEMoaB GmbH.
CK is employed by CMT Cellex Manufacturing Transports and Logistics GmbH. MW and HE …
CK is employed by CMT Cellex Manufacturing Transports and Logistics GmbH. MW and HE …
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
L Lu, M **e, B Yang, W Zhao, J Cao - Science Advances, 2024 - science.org
Chimeric antigen receptor T (CAR-T) cell therapy is a promising and precise targeted
therapy for cancer that has demonstrated notable potential in clinical applications. However …
therapy for cancer that has demonstrated notable potential in clinical applications. However …
Hurdles to breakthrough in CAR T cell therapy of solid tumors
F Marofi, H Achmad, D Bokov, WK Abdelbasset… - Stem Cell Research & …, 2022 - Springer
Autologous T cells genetically engineered to express chimeric antigen receptor (CAR) have
shown promising outcomes and emerged as a new curative option for hematological …
shown promising outcomes and emerged as a new curative option for hematological …
The black hole: CAR T cell therapy in AML
E Atilla, K Benabdellah - Cancers, 2023 - mdpi.com
Simple Summary Unlike B cell malignancies, the progress on generating an adoptive T cell
therapy for relapsed/refractory acute myeloid leukemia (AML) remains insufficient. This …
therapy for relapsed/refractory acute myeloid leukemia (AML) remains insufficient. This …
CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm
In spite of consistent progress at the level of basic research and of clinical treatment, acute
myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric …
myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric …
Theranostic cells: emerging clinical applications of synthetic biology
Synthetic biology seeks to redesign biological systems to perform novel functions in a
predictable manner. Recent advances in bacterial and mammalian cell engineering include …
predictable manner. Recent advances in bacterial and mammalian cell engineering include …